Abstract
With several successful anticancer drugs on the market and numerous compounds in clinical developments, antimitotic agents represent an important category of anticancer agents. However, clinical utility of the tubulin-binding agents is somewhat limited due to multiple drug resistance (MDR), poor pharmacokinetics and therapeutic index. There is ongoing need for the modulators of other intracellular targets that result in the same anti-mitotic effect without adverse effects of “traditional” tubulin binders. This review describes progress made to-date in development of novel and emerging biotargets affecting the mitotic events, and their small-molecule modulators.
Keywords: Antimitotic agents, mitotic kinesins, mitotic kinases, separase
Current Cancer Drug Targets
Title: Novel Mitotic Targets and Their Small-Molecule Inhibitors
Volume: 7 Issue: 8
Author(s): Alexandre V. Ivachtchenko, Alex S. Kiselyov, Sergey E. Tkachenko, Yan A. Ivanenkov and Konstantin V. Balakin
Affiliation:
Keywords: Antimitotic agents, mitotic kinesins, mitotic kinases, separase
Abstract: With several successful anticancer drugs on the market and numerous compounds in clinical developments, antimitotic agents represent an important category of anticancer agents. However, clinical utility of the tubulin-binding agents is somewhat limited due to multiple drug resistance (MDR), poor pharmacokinetics and therapeutic index. There is ongoing need for the modulators of other intracellular targets that result in the same anti-mitotic effect without adverse effects of “traditional” tubulin binders. This review describes progress made to-date in development of novel and emerging biotargets affecting the mitotic events, and their small-molecule modulators.
Export Options
About this article
Cite this article as:
Ivachtchenko V. Alexandre, Kiselyov S. Alex, Tkachenko E. Sergey, Ivanenkov A. Yan and Balakin V. Konstantin, Novel Mitotic Targets and Their Small-Molecule Inhibitors, Current Cancer Drug Targets 2007; 7 (8) . https://dx.doi.org/10.2174/156800907783220499
DOI https://dx.doi.org/10.2174/156800907783220499 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Investigational Positive Inotropic Agents for Acute Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Structure and Function of Poly(ADP-ribose) Polymerase-1: Role in Oxidative Stress-Related Pathologies
Current Vascular Pharmacology MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Memantine: Its Role in Vascular Dementia
Drug Design Reviews - Online (Discontinued) Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Kupffer Cell-Dependent Signaling in Thyroid Hormone Calorigenesis: Possible Applications for Liver Preconditioning
Current Signal Transduction Therapy Future Contrast Agents for Molecular Imaging in Stroke
Current Medicinal Chemistry Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design Subretinal Transplantation of Rat MSCs and Erythropoietin Gene Modified Rat MSCs for Protecting and Rescuing Degenerative Retina in Rats
Current Molecular Medicine Stem Cells in MDR-TB and XDR - TB
Current Respiratory Medicine Reviews Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Recent Advances Using Phosphodiesterase 4 (PDE4) Inhibitors to Treat Inflammatory Disorders: Animal and Clinical Studies
Current Drug Therapy SIRT1 as a Therapeutic Target in Diabetic Complications
Current Medicinal Chemistry Pharmacological Strategies for Neuroprotection in Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury
Current Neurovascular Research Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease
Current Drug Targets Facing Up the ROS Labyrinth - Where To Go?
Current Vascular Pharmacology The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry